Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors - Yahoo Finance
LOS ANGELES, October 21, 2021--(BUSINESS WIRE)--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your Novavax investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/novavax-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
On October 19, 2021 Politico reported that, while "Novavax recently attested to some of its [vaccine] analytics and testing issues in a quarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood." According to Politico, two people "with direct knowledge of the matter" claim Novavax "has struggled to attain anywhere close" to the 90 percent vaccine purity levels required to meet Food and Drug Administration guidance. The report continues, "[a]nother person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent" and that "[l]ow purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients."
On this news, Novavax’s share price fell $23.69, or almost 15%, to close at $136.86 per share on October 20, 2021, thereby injuring investors.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice: Persons with non-public information regarding Novavax should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
source: https://finance.yahoo.com/news/glancy-prongay-murray-llp-leading-232500738.html
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.